Evommune, Inc. (EVMN)
13.66
-0.36
(-2.57%)
USD |
NYSE |
Aug 24, 16:00
13.66
0.00 (0.00%)
After-Hours: 20:00
Evommune Shareholders Equity (Quarterly) : 277.59M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 277.59M |
| March 31, 2026 | 304.56M |
| December 31, 2025 | 205.57M |
| Date | Value |
|---|---|
| September 30, 2025 | -183.14M |
| June 30, 2025 | -171.23M |
| March 31, 2025 | -158.24M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | 348.30M |
| Mineralys Therapeutics, Inc. | 550.92M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 301.95M |
| Total Liabilities (Quarterly) | 24.36M |
| Debt to Equity Ratio | 0.0311 |
| Current Ratio | 11.68 |
| Net Debt Paydown Yield | 7.65% |